Thelansis

 Angioimmunoblastic T-cell Lymphoma (AITL) is a subtype of Peripheral T-cell Lymphoma (PTCL) arising from T-follicular helper cells. It is characterized by systemic symptoms such as generalized lymphadenopathy, hepatosplenomegaly, anemia, and hypergammaglobulinemia, with a median age of onset at around 60 years of age and no gender preference. More than 80% of patients with AITL present with advanced stage (III/IV) disease at the time of diagnosis, often accompanied by constitutional symptoms such as fever, chills, and weight loss. Mutations in epigenetic regulators TET2, DNMT3A, and IDH2 have been found in PTCL and are more frequent in AITL and T-cell lymphomas with a follicular helper T-cell phenotype. The presence of these mutations is linked to the RHOA G17V mutation, supporting a multistep model of T-cell transformation in AITL. The differential diagnosis for AITL includes reactive lymphoid hyperplasia, Hodgkin's disease, T-cell-rich large B-cell lymphoma, and other types of P...